Shella Saint Fleur-Lominy, MD, PhD

Shella Saint Fleur-Lominy, MD, PhD, discusses targeted pathways in myeloproliferative neoplasms.

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.

Shella Saint Fleur-Lominy, MD, PhD, discusses remaining challenges in myelofibrosis.

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

Shella Saint Fleur-Lominy, MD, PhD, discusses the role of transplant in myeloproliferative neoplasms.

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

Shella Saint Fleur-Lominy, MD, PhD, discusses the differences between ruxolitinib and fedratinib in the treatment of patients with myeloproliferative neoplasms.

Shella Saint Fleur-Lominy, MD, PhD, discusses the effects ruxolitinib has on symptom burden in patients with myeloproliferative neoplasms.